January 2026

Joined Nvidia Inception Programme for AI Startups

Doses AI has been admitted to the Nvidia Inception programme, which supports cutting-edge AI startups with hardware access, technical training, and go-to-market support. The programme gives Doses AI access to Nvidia's DGX Cloud infrastructure and preferred pricing on GPU compute.

About Nvidia Inception

Nvidia Inception is a free programme designed to help AI startups evolve faster through access to technology, expertise, and go-to-market support. The programme has nurtured over 18,000 startups globally, providing a path from early research through to scaled deployment. Members gain access to Nvidia's hardware ecosystem, deep learning training resources, and a network of venture capital partners.

For Doses AI, the programme addresses a core bottleneck in their development pipeline. Training ternary language models — where weights are constrained to {-1, 0, +1} — requires intensive matrix operations during the knowledge distillation phase. The continual pretraining stage of their distillation pipeline, which converts full-precision fp16 models into 1.58-bit ternary architectures, is computationally demanding and benefits directly from Nvidia's GPU acceleration.

About Nvidia Inception

Nvidia Inception supports AI startups with preferred pricing on Nvidia hardware and cloud instances, access to DGX Cloud for large-scale training, technical workshops with Nvidia engineers, and co-marketing opportunities. The programme is free to join and has no equity requirement.

Programme Benefits

Nvidia Inception provides Doses AI with resources that directly accelerate the development of the Doses Mortar model family:

Programme
Nvidia Inception
Infrastructure
DGX Cloud
Model Family
Doses Mortar
Training Pipeline
Ternary distillation
"Ternary training is paradoxically GPU-intensive — you need significant compute to produce models small enough to run without it. Nvidia's hardware ecosystem is the backbone of that pipeline." — Malik Ahmed, Founder & CEO, Doses AI
Doses AI · 2026